Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels

Biomarkers in Medicine

Volumn 8, Issue 2, 2014, Pages 239-245

  Gustafsson, Finn ^a   Gude, Einar ^b   Sigurdardottir, Vilborg ^c   Aukrust, Pål ^b,d   Solbu, Dag ^e   Goetze, Jens Peter ^a   Gullestad, Lars ^b,d  

^a Rigshospitalet   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF OSLO   (Norway)

^e Novartis Norway AS   (Norway)

Author keywords

biomarker; glomerular filtration; proliferation signal inhibitor; renal dysfunction

Indexed keywords

ACUTE-PHASE PROTEINS; AGED; CALCINEURIN; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOCALINS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; SIROLIMUS;

EID: 84894302685     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.95     Document Type: Article

References (29)

1. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: 27th Official Adult Heart Transplant Report - 2010. J. Heart Lung Transplant. 29(10), 1089-1103 (2010).
2. Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am. J. Transplant. 7(2), 461-465 (2007).
3. Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl. Int. 22(1), 78-89 (2009).
4. Gustafsson F, Ross HJ. Renal-sparing strategies in cardiac transplantation. Curr. Opin. Organ Transplant. 14(5), 566-570 (2009).
5. Aliabadi AZ, Pohanka E, Seebacher G et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am. J. Transplant. 8(4), 854-861 (2008).
6. Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J. Heart Lung Transplant. 26(10), 998-1003 (2007).
7. Gonzalez-Vilchez F, de Prada JA, Castrillo C, Canteli A, Llano MF, Martin-Duran R. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients. J. Heart Lung Transplant. 30(5), 552-557 (2011).
8. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268(14), 10425-10432 (1993).
9. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38(3), 414-420 (1996).
10. Yndestad A, Landro L, Ueland T et al. Increased systemic and myocardial expression of neutrophil gelatinase-Associated lipocalin in clinical and experimental heart failure. Eur. Heart J. 30(10), 1229-1236 (2009).
11. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-Associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 24(3), 307-315 (2004).
12. Viau A, El Karoui K, Laouari D et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Invest. 120(11), 4065-4076 (2010).
13. Wasilewska A, Zoch-Zwierz W, Taranta- Janusz K, Michaluk-Skutnik J. Neutrophil gelatinase-Associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr. Nephrol. 25(5), 889-897 (2010).
14. Lebkowska U, Malyszko J, Lebkowska A et al. Neutrophil gelatinase-Associated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study. Transplant. Proc. 41(1), 154-157 (2009).
15. Niemann CU, Walia A, Waldman J et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-Associated lipocalin. Liver Transpl. 15(12), 1852-1860 (2009).
16. Przybylowski P, Malyszko J, Malyszko JS. Serum neutrophil gelatinase-Associated lipocalin correlates with kidney function in heart allograft recipients. Transplant. Proc. 42(5), 1797-1802 (2010).
17. Abraham BP, Frazier EA, Morrow WR et al. Cystatin C and neutrophil gelatinase-Associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr. Transplant. 15(6), 564-569 (2011).
18. Szewczyk M, Wielkoszynski T, Zakliczynski M, Zembala M. Plasma neutrophil gelatinase-Associated lipocalin (NGAL) correlations with cystatin C, serum creatinine, and glomerular filtration rate in patients after heart and lung transplantation. Transplant. Proc. 41(8), 3242-3243 (2009).
19. Galichon P, Vittoz N, Xu-Dubois YC et al. Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage. Transplantation 92(9), 993-998 (2011).
20. Gullestad L, Iversen M, Mortensen SA et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 89(7), 864-872 (2010).
21. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV. Neutrophil gelatinase-Associated lipocalin (NGAL): validation of commercially available ELISA. Scand. J. Clin. Lab. Invest. 70(5), 374-382 (2010).
22. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39(2 Suppl. 1), S1-S266 (2002).
23. Parikh CR, Jani A, Mishra J et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 6(7), 1639-1645 (2006).
24. Kusaka M, Kuroyanagi Y, Mori T et al. Serum neutrophil gelatinase-Associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant. 17(1-2), 129-134 (2008).
25. Portal AJ, McPhail MJ, Bruce M et al. Neutrophil gelatinase-Associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transpl. 16(11), 1257-1266 (2010).
26. Malyszko J, Malyszko JS, Mysliwiec M. Serum neutrophil gelatinase-Associated lipocalin correlates with kidney function in renal allograft recipients. Clin. Transplant. 23(5), 681-686 (2009).
27. Wagener G, Minhaz M, Mattis FA, Kim M, Emond JC, Lee HT. Urinary neutrophil gelatinase-Associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol. Dial. Transplant. 26(5), 1717-1723 (2011).
28. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Salmela KT. Urine neutrophil gelatinase-Associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int. 79(1), 89-98 (2011).
29. Bolignano D, Coppolino G, Aloisi C, Romeo A, Nicocia G, Buemi M. Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-Associated lipocalin levels in proteinuric patients with normal renal function. J. Investig. Med. 56(8), 997-1003 (2008).